Acer Therapeutics Inc. (ACER) News
Filter ACER News Items
ACER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ACER News From Around the Web
Below are the latest news stories about ACER THERAPEUTICS INC that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?Acer Therapeutics (ACER) stock is taking off on Thursday after the company announced an acquisition deal with Zevra Therapeutics (ZVRA). |
Shopify (SHOP) Stock Jumps 6% on Amazon DealShopify (SHOP) stock is on the rise Thursday as investors react to a deal between it and e-commerce giant Amazon (AMZN). |
Why Is Axcella Health (AXLA) Stock Down 21% Today?Axcella Health (AXLA) stock is falling on Thursday following a rally from its announcement of a new Covid-19 treatment patent. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for another breakdown of the biggest pre-market stock movers as we dive into all of the latest news for Thursday! |
Struggling Newton biotech Acer Therapeutics scooped up by Florida firmCelebration, Florida's Zevra Therapeutics Inc. is set to buy Acer Therapeutics Inc. in a deal worth up to $91 million. |
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductProposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra’s revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™ |
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Li |
Acer Therapeutics, funded almost entirely by its own CEO, has weeks to liveA Newton biotech has just a few weeks of cash runway as it struggles to commercialize its recently approved urea cycle disorder drug. |
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateOLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patientsNEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The second |
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderPromissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has received $1,000,000 in funding in exchange for the issuance of an u |